 |
|
|---|---|
| Fecal microbiota spores, live—brpk (Vowst) |
Restricted to ID/ASP for use in select adults with recurrent CDI who are expected to be hospitalized > 14 days after C. difficile episode. |
| Eravacycline |
Restricted to ID or Antimicrobial Stewardship |
| Daptomycin |
Restricted to ID or Antimicrobial Stewardship |
| Dalbavancin |
Restricted to ID or Antimicrobial Stewardship |
| Colistin IV |
Restricted to ID or Antimicrobial Stewardship *Inhaled use of colistin is allowed for unrestricted use in prophylaxis in lung transplant. |
| Cidofovir |
Restrict to ID or Antimicrobial Stewardship except: 1) For treatment or prophylaxis against viral infection in a BMT patient |
| Ceftolozane/tazobactam (Zerbaxa) |
Restricted to ID or Antimicrobial Stewardship |
| Ceftazidime/avibactam (Avycaz) |
Restricted to ID or Antimicrobial Stewardship |
| Ceftaroline |
Restricted to ID or Antimicrobial Stewardship |
| Cefiderocol |
Restricted to ID or Antimicrobial Stewardship |
| Bezlotoxumab |
Restricted to ID or Antimicrobial Stewardship Additonal criteria for inpatient administration: Must be expected to be hospitalized > 14 days after C. difficile episode |
| Baloxavir marboxil |
Restricted to ID or Antimicrobial Stewardship |
| Artesunate |
Restricted to ID or Antimicrobial Stewardship |
| Amikacin |
Restricted to ID or Antimicrobial Stewardship for IV amikacin |
| AmBisome (liposomal amphotericin B) |
Restricted to ID or Antimicrobial Stewardship except: 1) Documented or suspected fungal pneumonia in a patient intolerant of or with contraindications to azoles 2) Prophylaxis against fungal infections in patients on the hematology/BMT service or lung transplant service 3) Empiric therapy for prolonged febrile neutropenia in hematology/oncology/BMT patient |